Here, we provide evidence that RNaseH2 inhibitor candidates can reduce glioma cell survival, particularly in high-grade gliomas with IDH1 wild-type status, a subtype characterized by its aggressiveness and treatment resistance. The gene discussed is IDH1; the disease is glioma.